Let’s be honest: endometriosis has long been one of the most underdiagnosed and misunderstood medical conditions in women's health. A silent disruptor, it causes pain, fertility issues, and decades-long suffering, often without a name. Until now, the only path to a diagnosis was invasive laparoscopic surgery, usually after seven years of misdiagnosis. That’s not a system built for healing. But what if we could change that narrative with a simple blood test?

In a world where the AI narrative is being woven into every corner of enterprise, education is often spoken about but seldom transformed at scale. That’s why OpenLearning Limited (ASX: OLL) stands out. It’s not just deploying AI – it’s integrating it meaningfully into a software-as-a-service (SaaS) platform that’s already showing traction in major education markets.

Arika Resources (ASX: ARI) has doubled down on discovery with a 40% expansion of its upcoming drilling campaign across the Yundamindra and Kookynie Gold Projects. With a strengthened balance sheet and an ambitious exploration strategy, the company is stepping firmly into the spotlight of Western Australia’s gold narrative.

When it comes to development-ready assets, timing is everything. Larvotto Resources has just released a highly compelling Definitive Feasibility Study (DFS) for its Hillgrove Antimony-Gold Project in New South Wales—and it’s arrived at the right time. Gold prices are flying. Antimony prices are surging. Even tungsten is starting to catch a bid. Hillgrove is set to become a key player in a world hungry for critical minerals and strategic metals.

The Radium Hill Project in South Australia has long held historical significance as the site of the country’s first major uranium mine. What was once seen primarily as a uranium deposit is now re-emerging as a polymetallic system rich in scandium and rare earth elements (REEs). With new assays from Heavy Rare Earths Limited (ASX: HRE), this overlooked potential is becoming increasingly apparent—and economically compelling.

When we talk about "high-grade" in gold exploration, the term can sometimes lose its meaning in a market awash with numbers and drilling updates. But now and then, an announcement cuts through the noise, and Aurumin's latest results from the Gwendolyn deposit at the Johnson Range Gold Project do just that.

If there was ever a time when a company needed to make a statement, it’s in the first weeks after acquiring a new asset. And for Kaiser Reef Limited (ASX:KAU), their early run at the Henty Gold Mine hasn’t just been good—it’s been headline-worthy.

Macro Metals (ASX:M4M) is not chasing headlines, and that’s exactly why it stands out. In a sector often dominated by bold claims and speculative positioning, Macro is taking the quieter but arguably more resilient approach—scaling into a dual-core strategy of iron ore exploration and fully integrated mining services.

In a world grappling with stress and sleeplessness, The Calmer Co. International Limited (ASX: CCO) is emerging as a standout in the wellness beverage market. This Brisbane-based company, known for its innovative kava-infused offerings, has just posted a headline-grabbing 104% year-on-year growth in Amazon USA sales, reaching AUD $203,000 in April 2025 alone.

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) has made a decisive move with its proposed acquisition of StemSmart™, a patented mesenchymal stromal cell (MSC) technology. This isn’t just another biotech transaction — it signals a strategic leap into the fast-growing field of regenerative medicine, positioning NSB to capitalise on one of the most promising frontiers in modern healthcare.